Evidence Table 120. KQ3—Dichotomous—Asparatate aminotransferase (AST) raised

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Davidson200714Parallel | > 3.0 x ULN | Unclear | Simvastatin (40) | Omega-3 | 122 | 0 | Placebo | 132 | 0 | NR |  | Medium |
| Napoli199852Parallel | Data imputed- there were no differences between baseline and post treatment values. | Unclear | Pravastatin (20-40) | Vitamin E |  | 0 | No Treatment |  | 0 |  | No differences in routine laboratory tests or adverse events were registered during the study in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups. | Medium |
| Chan200212Parallel | thresholds not specified | At moderate/moderately high risk for CHD (2+ risk factors) | Atorvastatin (40) | Omega-3 | 11 | 0 | No Treatment | 13 | 0 |  |  | Medium |
| Liu200337Parallel | thresholds not specified | Unclear | Simvastatin (10) | Omega-3 | 19 | 0 | No Treatment | 18 | 0 |  |  | Medium |

Evidence Table 120. KQ3—Dichotomous—Asparatate aminotransferase (AST) raised (continued)

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Young200770Parallel | > 3 times the upper level of normal | Mixed:Mod and high risk | Simvastatin (10-40) | Co-Q10 | 22 | 0 | Placebo | 22 | 0 | NR | Exclusion criteria included: alanine aminotransferase or aspartate aminotransferase > 3 times the upper level of normal and results state: "Liver... function, …[was] not altered with either regime." Thus, counts of 0 and 0 were added for each arm | Medium |
| Gosai200826Crossover | reference range males: 0-46 U/L; females: 0-36 U/L | At low risk for CHD (0-1 risk factors) | Rosuvastatin (40) | Omega-3 | 48 | 0 | No Treatment | 48 | 2 |  | N/A | Medium |
| Di Spirito200819Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 | 9 | No Treatment | 50 | 13 |  | N/A | Medium |
| Balestrieri19964Crossover | N/A | Mixed:Low and/or mod to high risk | Simvastatin (10-40) | Omega-3 | 14 | 0 | Placebo | 16 | 0 |  | N/A | Medium |
| Paolissa199256Crossover | N/A | At high risk for CHD | Nifedipine (88) | Vitamin E |  | 0 | Placebo |  | 0 |  | N/A | Medium |
| Watson199966Crossover | N/A | At high risk for CHD | ACE inhibitors (no description), furosemide, digoxin, also hydralazine and/or nitrates (NR) | Co-Q10 |  | 0 | Placebo |  | 0 | NR | N/A | Medium |